Surviving Melanoma in Europe.  

Access to prevention, early detection and effective treatment for all.

Melanoma Patient Network Europe

This conference would have not been possible without the Financial support from
















The conference was funded by all sponsors to equal parts. Sponsors have had no influence on the program, faculty or any other editorial content of this conference or website. 

Conference participation is free and includes accommodation and support for travel for patient advocates. Neither participants nor faculty receive honoraria for attendance. 




m-icab Conference 2014


Date and location


28th- 30th march 2014


HOTEL MARIVAUX BRUSSELS
Boulevard Adolphe Max 98

1000 Brussels - Belgium



Free accommodation and travel support for patient advocates

GSK- logo coming


Patient participation in Melanoma clinical research

28th- 30th March 2014 in Brussels



joint M-icab/ ESO conference



Recent unprecedented progress in melanoma therapies provide for the first time hope for patients in advanced stages of the disease. However, navigating a fast-evolving treatment landscape presents a real challenge, not only for patients but also their advocates.
With novel treatments in development, the most promising agents are often only accessible in a clinical trial setting. For this reason, access to and participation in clinical studies strongly shape the reality for stage 4 and increasingly, also stage 3 melanoma patients.

The current logistical, ethical and humane challenges to melanoma patients’ enrolment in clinical trials now appeal for a change of paradigm in the design and conduct of these trials. 


The topic of this conference is therefore patient-centred clinical trial design in Melanoma and the different stakeholders (patients, clinicians, regulators, HTA and industry) will contribute their perspectives to whether alternative licensing models- such as adaptive licensing- are better suited to address the needs of Melanoma patients. 


The focus of the second day of the conference is Melanoma patient advocacy in Europe and how we as advocates can make use of the newly founded Melanoma Patient Network Europe to exchange know-how and collaborate effectively on European issues in Melanoma.

There will be plenty of opportunity for patient advocates to meet, including a poster session for advocacy organisations to present themselves and their most successful advocacy projects!


We are looking forward to meeting you in Brussels!


Bettina Ryll, Conference Chair